Blog post
Multiple Myeloma Patient and Support Group Co-Leader Diane Phipps Shares Her Perspective on the Myeloma Community A Diagnosis and a Turning PointIn an interview with the International Myeloma Foundation (IMF), Diane Phipps shared something she has come to believe deeply about living with…
Event
The International Myeloma Foundation Presentations will take place 4:00 PM - 7:00 PM ET Date and Location: Friday, June 19, 2026Rev. Dr. James Kilgore, PastorFriendship Baptist Church144 W. 131st StreetNew York, NY 10027 Register…
Blog post
ASH 2025 Multiple Myeloma Breakthroughs: Key Trial ResultsScope and Methodology This week’s blog summarizes breakthrough myeloma abstracts presented by IMF Scientific Advisory Board (SAB) and International Myeloma Working Group (IMWG) members at the 67th American Society…
Blog post
Multiple Myeloma Treatment Advances at ASH 2025: A Patient’s TakeBy Jim Shoemaker #1 Abstract Title: Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma.I want to begin by saying this plainly: I am not in the…
Blog post
A summary of some notable key multiple myeloma research from November-December 2025 Scope and MethodologyThis week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from November-December 2025. Content was…
Blog post
MGUS and Smoldering Myeloma at ASH 2025: What’s NewBy Jessie Daw, PhDThe 2025 American Society of Hematology (ASH) meeting moved fast, and attending virtually didn’t slow the pace. As a virtual member of the International Myeloma Foundation’s (IMF) Myeloma Voices team, I was busy,…
Blog post
Dr. Shaji Kumar on Smoldering Myeloma, High-Risk Disease & What’s Next Scope and Methodology This week’s blog summarizes the top takeaways from a recent Q&A interview with IMF Scientific Advisory Board Member and IMWG Member Dr. Shaji Kumar (Mayo Clinic —…
Blog post
Faster Myeloma Progress: ASH 2025 Takeaways on CAR-T and New DrugsBy Jill Zitzewitz, PhD The day before the American Society of Hematology (ASH) meeting kicks off each year is Satellite Symposia Day, where community oncologists can attend and receive continuing education…
Blog post
ASH 2025 Myeloma Satellite Symposium: SMM, Quad Therapy & SDMBy Jessie Daw, PhDI was up and at’em for my first session, which began at 6:30AM Central time. This session, Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment, looked…
Blog post
IMS 2025 Highlights in Multiple Myeloma Treatment The 22nd International Myeloma Society (IMS) Annual Meeting was held from September 17–20, 2025 in Toronto, Canada. By Dr. Joseph Mikhael IMF Chief Medical Officer Scope and MethodologyThis…
Blog post
October and November 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage,…
Blog post
Key Takeaways from the 2025 IMWG, ASCO, and EHA ConferencesEvery year, three annual events take place in quick succession — ASCO, IMWG, and EHA. These highly-anticipated meetings hold special significance for researchers and clinicians working in the field of myeloma. By Dr. Joseph MikhaelIMF…
Blog post
Myeloma and Health Equity: One Patient’s Fight for Better CareThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Blog post
2025 Iceland Cycling Expedition: Riding to End Multiple MyelomaFrom August 27 – September 2, a team of 20 iron-willed individuals — myeloma patients, care partners, doctors, researchers, and industry partners alike — embarked on another unforgettable 150-mile cycling expedition of Iceland’s…
News Article
2026 MAM Global Campaign Demonstrates the Spirit of #MoreThanMyelomaOver 60 million in 96 countries celebrate resilience, strengthen connections, and inspire hopeBy Peter Anton, IMF Vice President, MarketingAs the 2026 Myeloma Action Month (MAM) annual global awareness campaign…
Videos
What “Cure” Really Means in Multiple Myeloma | MRD & Long-Term Remission ExplainedCan multiple myeloma actually be cured? For the first time, myeloma researchers and clinicians are formally discussing and defining what “cure” could mean for patients living with multiple myeloma.In this video,…
Blog post
"The ongoing care for myeloma is a marathon, not a sprint. And all throughout, resilience will, undoubtedly, need to be enhanced." — IMF Co-Founder Dr. Brian G.M. Durie (1942-2025)
As a fitting tribute to Dr. Brian G.M. Durie — a…
Blog post
2025 Myeloma Policy Updates: Medicare $2,000 Cap, Parity & Medicaid Access An informative discussion with International Myeloma Foundation (IMF) Director of Public Policy and Advocacy Danielle Doheny on U.S. policy updates, Medicare cap, drug parity, telehealth and other relevant issues…
Blog post
MGUS & Smoldering Myeloma in 2025: iStopMM Screening and Risk Updates The iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study in…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Blog post
An informative conversation between IMF Chief Medical Officer Dr. Joseph Mikhael and IMF Scientific Advisory Board Member Dr. Shaji Kumar on what myeloma patients and their families should expect next in terms of early screening and diagnosis, treatments, and care.
On the second…
Blog post
Myeloma Misdiagnosis to CAR-T Remission: A Survivor’s Advocacy StoryThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
Key Takeaways from the IMF Facebook Live on Myeloma Clinical Trials On Saturday, July 19, International Myeloma Foundation (IMF) Chief Medical Officer Dr. Joseph Mikhael — along with SparkCures Founder & CEO Brian McMahon and 20-year myeloma patient and advocate Thomas Goode — hosted a…
Blog post
July and August 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed…
Blog post
The International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will help raise awareness about the disease, inspire action…
Blog post
On Tuesday, July 1, the International Myeloma Foundation conducted its annual webinar, “Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient…
Blog post
On Tuesday, July 1, the International Myeloma Foundation conducted its annual webinar on “Top Myeloma Research Presented at ASCO, EHA, & IMWG 2025 Webinar: The Patient…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community.
…
Blog post
Myeloma Research Updates: Key Takeaways from ASCO, EHA & IMWG
Every year, three annual events that take place in quick succession hold a special significance for the researchers and clinicians working in the field of myeloma. The 2025 annual meeting of the American Society of Clinical…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
On Tuesday, June 17, the International Myeloma Foundation (IMF) conducted its annual webinar on the 2025 IMWG Conference Series: Making Sense of Treatment.
The webinar was hosted by IMF Chief Medical Officer Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO (TGen at the City of…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
State of Myeloma 2025: New Treatments & Research
With very encouraging data and results of various myeloma research efforts unveiled at the 2025 American Society of Clinical Oncology (ASCO) annual summit in Chicago, IL, and the European Hematology Association (EHA) Congress in Milan, Italy,…
Blog post
ODAC finds sufficient evidence that benefits outweigh risks; supports treating HR-SMM patients with daratumumab and hyaluronidase-fihj
On Tuesday, May 20, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) “voted (6-2) in favor of the benefit-risk…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. Through these…
Blog post
A Closer Look at A Study on the Global and Regional Burden of Myeloma Among Patients Aged 40 and Over
A recent study published in Scientific Reports, Trends and projections of the global and regional burden of multiple…
Blog post
Medical Student Scholar Tyra Grischke and Dr. Ben Derman talk about their collaborative study in a Q&A with the IMF
On March 28, Blood Cancer Journal published the study, “Brain-to-vein and vein-to-vein times and…
Blog post
Myeloma Experts Drs. Joseph Mikhael and Rafat Abonour Discuss the Future of Myeloma
By Joseph Mikhael MD, MEd, FRCPC, FACP, FASCO
IMF Chief Medical Officer
When I started my work in myeloma more than 20 years ago, it was truly a terrible disease, and most…
Blog post
Taking a Deeper Dive into the IMF's iStopMM Study
Principal Investigator Sigurður Yngvi Kristinsson, MD, PhD provides insights on the iStopMM Project and delves into why the ambitious research trial is headed toward finding a cure for myeloma.
If you are part of the IMF’s myeloma…
Page
Remission vs. Cure: Understanding the Difference in Multiple MyelomaRemission is when the signs and symptoms of multiple myeloma, including the key tests that measure the disease, are reduced or have disappeared. This can occur in different levels, including partial, very good partial response (…
Page
How Long Can You Live With Multiple Myeloma?As with any chronic disease, life expectancy statistics can vary among individuals, depending on the stage of detection and risk factors. Recent published studies have shown the average multiple…
IMF Person
Randy Marsh is an experienced nonprofit operations executive with over 20 years’ experience leading teams managing HR, Finance, Accounting, IT, Contract, Legal, and Facilities in nonprofit, government, and for-profit organizations. Randy has spent over a decade serving on nonprofit boards,…
Blog post
On Saturday, March 15, IMF Chief Medical Officer Joseph Mikhael MD, MEd, FRCPC, FACP, FASCO, along with IMF Vice President of Development Sylvia Dsouza, hosted a Facebook Live Q&A session in Boca Raton, FL to answer the most pressing questions about myeloma care, myeloma research, and…
Blog post
On Thursday, March 6th, IMF Scientific Advisory Board Member, and Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center Saad Z. Usmani, MD, MBA, FACP, FASCO hosted a live Q&A session on Facebook to answer the most pressing questions about multiple myeloma as…
Blog post
The International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will help raise awareness about the…
Blog post
Prior Authorization Delays in Myeloma Care: A Patient’s Fight for RevlimidThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the first course of the Legislative Advocacy Master Class (LAMC). The IMF hopes that…
Blog post
Bryan Soronson Advocates for Myeloma Clinical Trials
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation (IMF) is excited to share this collection of patient and care partner stories from those who have completed the first course of the Legislative…
Blog post
35 Years of Myeloma Progress at the IMF This year’s Myeloma Action Month (MAM) is especially significant for the International Myeloma Foundation. In 2025, we will be celebrating our 35th anniversary—the perfect occasion to recollect 35 years of meaningful myeloma milestones, as we look…
Blog post
A Myeloma Patient with a Mission: Coaching and Advocacy
With Myeloma Action Month (MAM) taking place this March, the International Myeloma Foundation is excited to share this collection of patient and care partner stories from those who have completed the first course of the…